• Innovent Biologics on Nov. 12, 2026, reported its first preclinical IAR177 data presentation at ACR Convergence in Orlando, Florida.
• The IL-6 x TL1A bispecific antibody outperformed single-target blockade in laboratory and animal models of rheumatoid arthritis.
• Preclinical findings support development of a high-concentration formulation for infrequent subcutaneous dosing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611121900PR_NEWS_USPR_____CN96293) on November 13, 2026, and is solely responsible for the information contained therein.